152808-60-1 Usage
Uses
Used in Plastics and Coatings Industry:
3-(2-methoxyethoxy)benzoic acid is used as an intermediate in the production of benzotriazole UV stabilizers for [application reason] protecting plastics and coatings from the degrading effects of ultraviolet radiation, thereby enhancing their durability and longevity.
Used in Pharmaceutical Industry:
3-(2-methoxyethoxy)benzoic acid is used as a building block in the synthesis of pharmaceuticals for [application reason] its versatile chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
3-(2-methoxyethoxy)benzoic acid is used as a building block in the synthesis of agrochemicals for [application reason] its chemical properties make it suitable for the creation of compounds that can be used in agricultural settings to protect crops or enhance growth.
Check Digit Verification of cas no
The CAS Registry Mumber 152808-60-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,2,8,0 and 8 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 152808-60:
(8*1)+(7*5)+(6*2)+(5*8)+(4*0)+(3*8)+(2*6)+(1*0)=131
131 % 10 = 1
So 152808-60-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H12O4/c1-13-5-6-14-9-4-2-3-8(7-9)10(11)12/h2-4,7H,5-6H2,1H3,(H,11,12)
152808-60-1Relevant academic research and scientific papers
BICYCLIC COMPOUNDS
-
, (2020/06/01)
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.
Chemical compounds
-
, (2008/06/13)
The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
